Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CuraGen and TopoTarget initiate phase I cancers trial
This trial is being sponsored by the US National Cancer Institute (NCI) under a clinical trials agreement with CuraGen for the development of PXD101. The phase I trial
This trial is being sponsored by the US National Cancer Institute (NCI) under a clinical trials agreement with CuraGen for the development of PXD101. The phase I trial
This approval is the first in the world for a new class of oral drugs for type 2 diabetes, namely dipeptidyl peptidase-4 (DPP-4) inhibitors, which enhance the body’s
There are two CFC-free inhalers available on the UK market that contain the active substance beclometasone dipropionate, namely Trinity-Chiesi Pharmaceuticals’ Clenil Modulite and Ivax Laboratories’ Qvar. However these
The peptidic extract demonstrated significant results in reducing in vitro and in vivo IL-4 production by immune cells. The general consensus is that atopic dermatitis, or eczema, is
Under the terms of the new agreement, Balchem will provide its Pharmashure taste-masking technology for Auriga to utilize in its prescription pain products. This micro-encapsulation technology provides a
The phase II proof-of-concept clinical trial was a randomized, double-blind comparison of three doses of INS50589 to placebo by intravenous infusion and was targeted to enroll approximately 160
The study found that people with treatment-resistant depression experienced symptom relief in as little as two hours with a single intravenous dose of ketamine, which is usually used
Advanced Viral Research said that, although preliminary, this study, which was conducted using pigs, provides the rationale for advancing AVR 118 to the human testing stage. “This study
AZD-103 is part of an emerging class of disease-modifying drugs that have the potential to both reduce disease progression and improve symptoms such as cognitive function. In addition,
The rules governing minor changes to labeling and patient information leaflets can cost individual companies thousands of pounds and these costs are often passed on to the consumer